Publication details
Sotyku - Mechanismus účinku a účinnost v léčbě psoriázy
| Title in English | Sotyktu – mechanism of action and efficacy in the treatment of psoriasis |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | NEČAS, Miroslav. Sotyku - Mechanismus účinku a účinnost v léčbě psoriázy (Sotyktu – mechanism of action and efficacy in the treatment of psoriasis). In Trýbův dermatologický den. 2024. |
| Description | Deukravacitinib (SOTYKTU) is a highly selective tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of moderate to severe psoriasis in adult patients eligible for systemic therapy. TYK2 signaling plays an essential role in the pathogenesis of many inflammatory diseases, including psoriasis. Deukravacitinib represents a new oral treatment option for psoriasis that is likely to be significantly more effective than apremilast. |